South Carolina Paid Clinical Trials

A listing of 1173 clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Clinical Trials

South Carolina

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Location

Filter by Age

South Carolina is currently home to 1173 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Featured Trial

Chronic Kidney Disease (CKD) Clinical Study

Recruiting

A clinical study for people that suffer with Chronic Kidney Disease (CKD)

Conditions:

Chronic Kidney Disease (CKD)

Learn More

Featured Trial

Ischemic heart disease (IHD) Clinical Study

Recruiting

A clinical study for people that suffer with Ischemic heart disease (IHD)

Conditions:

Ischemic heart disease (IHD)

Learn More

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751

Recruiting

This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Noema TTS-201 Site #73, North Charleston, South Carolina

Conditions: Tourette Syndrome

Learn More ›

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Recruiting

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

07/29/2025

Locations: Palmetto Gastroenterology Clinical Research, Summerville, South Carolina

Conditions: Inflammatory Bowel Diseases, Crohn's Disease

Learn More ›

Weekly Isotretinoin vs Tetracycline for Moderate Acne

NCT06225570

Recruiting

In the effort to find better treatments for Moderate Acne, which often relies on long-term antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin A derivative, is highly effective for severe acne, its side effects limit its use for milder cases. A recent study from our institution investigated a new approach: weekly Isotretinoin dosing. The results were promising, with acne improvement and no major side effects. This suggests that weekly Isotretinoin could b... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Acne Vulgaris

Learn More ›

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

NCT06205342

Recruiting

This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Chronic Pancreatitis, Chronic Pain

Learn More ›

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

NCT06184750

Recruiting

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.

Gender:

FEMALE

Ages:

Between 18 years and 55 years

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma

Learn More ›

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457

Recruiting

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Coastal Carolina Research Center - North Charleston, North Charleston, South Carolina

Conditions: Episodic Migraine

Learn More ›

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444

Recruiting

The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 3 periods: 1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either a dose "A" or dose "B" of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B"). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Coastal Carolina Research Center - North Charleston, North Charleston, South Carolina

Conditions: Chronic Migraine

Learn More ›

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842

Recruiting

The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Primary Biliary Cholangitis (PBC)

Learn More ›

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578

Recruiting

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/29/2025

Locations: Velocity Clinical Research - Columbia- Site Number : 8401176, Columbia, South Carolina

Conditions: Dermatitis Atopic

Learn More ›

Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

NCT05024773

Recruiting

This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting of 12 weekly intravesical instillations of ONCOFID-P-B (induction phase). Patients with residual CIS at the end of induction treatment are eligible to enter a re-induction course of therapy (reinduction phase). Patients with stable disease by Investigator assessment defined as neither increased or decreased in extent or severity compared to baseline, are not eligible for re-induction therapy. Patients who achieve a complete resonde (CR) at the end of the induction or re-induction phase enter in the maintenance phase and receive monthly intravesical instillations of ONCOFID-P-B for an additional 12 monsthe or untile recurrence of CIS/HG Ta-T1 or progression to MIBC or extravesical disease. Patients who do not achieve a CR at the end of induction or re-induction phase, will discontinue investigational treatement and are followed up until month 48 from induction or re-induction start, or until a new antitumor therapy is initiated, wichever occurs first. Tumor response is evaluated by cystoscopy, cytology and biopsy at the end of the induction and re-induction phases and at Safety Follow Up Visit (SFUV). During the maintenance/follow-up period, tumorresponse is evaluated by cystoscopy and cytology every 3 months for up to 24 months from induction or re-induction start, and then every 6 months for an additional 2 years (long-term follow-up). Tumor biopsies are performed in case of of positive cystoscopy and/or cytology. Random biopsies are to be performed at 6, 12 and 18 months after the end of the induction or re-induction phase in responding patients (i.e. at 9, 15 and 21 months after induction or re-induction start. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina

Conditions: Bladder Carcinoma in Situ (CIS)

Learn More ›

Anesthetics and Analgesics in Children

NCT03427736

Recruiting

The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

Gender:

ALL

Ages:

Between 0 years and 17 years

Trial Updated:

07/29/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Anesthesia, Pain

Learn More ›

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180

Recruiting

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

Gender:

ALL

Ages:

All

Trial Updated:

07/29/2025

Locations: Not set, Columbia, South Carolina

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Learn More ›